Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies
Open Access
- 22 January 2019
- journal article
- research article
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 24 (1) , 48-55
Abstract
Intravenous immunoglobulin (IVIG) is a potential therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). To investigate the efficacy and safety of the IVIG IgPro10 (Privigen) for treatment of CIDP, results from Privigen Impact on Mobility and Autonomy (PRIMA), a prospective, open‐label, single‐arm study of IVIG in immunoglobulin (Ig)‐naïve or IVIG pre‐treated subjects (NCT01184846, n = 28) and Polyneuropathy And Treatment with Hizentra (PATH), a double‐blind, randomized study including an open‐label, single‐arm IVIG phase in IVIG pre‐treated subjects (NCT01545076, IVIG restabilization phase n = 207) were analyzed separately and together (n = 235). Efficacy assessments included change in adjusted inflammatory neuropathy cause and treatment (INCAT) score, grip strength and Medical Research Council (MRC) sum score. Adverse drug reactions (ADRs) and ADRs/infusion were recorded. Adjusted INCAT response rate was 60.7% in all PRIMA subjects at Week 25 (76.9% in IVIG pre‐treated subjects) and 72.9% in PATH. In the pooled cohort (n = 235), INCAT response rate was 71.5%; median time to INCAT improvement was 4.3 weeks. No clear demographic differences were noticed between early (responding before Week 7, n = 148) and late responders (n = 21). In the pooled cohort, median change from baseline to last observation was −1.0 (interquartile range −2.0; 0.0) point for INCAT score; +8.0 (0.0; 20.0) kPa for maximum grip strength; +3.0 (1.0; 7.0) points for MRC sum score. In the pooled cohort, 271 ADRs were reported in 105 subjects (44.7%), a rate of 0.144 ADRs per infusion. This analysis confirms the efficacy and safety of IgPro10, a recently FDA‐approved IVIG for CIDP, in a population of mainly pre‐treated subjects with CIDP [Correction added on 14 March 2019 after first online publication: the INCAT response rate has been corrected.].Keywords
Funding Information
- CSL Behring (N/A)
This publication has 19 references indexed in Scilit:
- Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single‐arm, open‐label Phase III study (the PRIMA study)Journal of the Peripheral Nervous System, 2013
- Advances in the diagnosis, pathogenesis and treatment of CIDPNature Reviews Neurology, 2011
- Safety and Tolerability of Immune Globulin Intravenous in Chronic Inflammatory Demyelinating PolyradiculoneuropathyArchives of Neurology, 2010
- Timing and Course of Clinical Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating PolyradiculoneuropathyArchives of Neurology, 2010
- Treatment of Chronic Inflammatory Demyelinating PolyneuropathyCurrent Treatment Options in Neurology, 2010
- European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First RevisionEuropean Journal of Neurology, 2010
- Incidence and prevalence of CIDP and the association of diabetes mellitusNeurology, 2009
- Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: Study of a UK populationMuscle & Nerve, 2009
- Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese populationJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trialThe Lancet Neurology, 2008